Arev produces and delivers functional ingredients from its world-class extraction systems. Arev is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. Arev is also working with pharmacy and dispensary operators with an innovative emulsified base formula to disperse cannabis oil extracts from specific selected genetic cannabis strains that address five areas of health, including anxiety, pain management, insomnia, central nervous system disorders and libido.

1. INVESTOR PRESENTATION
July 2018
GENETICS | CULTIVATION | EXTRACTION | FINISHED PRODUCTS
AREV Nutrition Sciences Inc.

2. The information set forth in this document contains “forward-looking statements.” Statements in this document, which are not purely historical, are forward
looking and include statements regarding beliefs, plans, expectations or intentions regarding the future.
Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.
Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as “estimate,” “anticipate,” “believe,”
“plan,” “intend,” “expect,” “may,” “should,” or similar statements are forward-looking statements. Risks and uncertainties for the Company include, but are not
limited to, the risks associated with the impact of general economic conditions in countries in which the Company conducts business, the impact of competitive
products and pricing, product demand and market acceptance, new product development, the continuation and development of key customer and supplier
relationships, and the availability of high-quality, qualified personnel and management. Other risks include, but are not limited to, factors affecting development
and expansion activities generally including access to capital to meet all of the Company’s financial requirements and the Company’s ability to control costs. There
can be no assurance that the Company’s efforts will succeed and the Company will ultimately achieve sustained commercial success. These forward-looking
statements are made as of the date of this document, and the Company assumes no obligation to update the forward-looking statements, except as required by
applicable securities laws, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
Although the Company believes that the beliefs, plans, expectations and intentions contained in this document are reasonable, there can be no assurance those
beliefs, plans, expectations or intentions will prove to be accurate.
This information contained in the document has been prepared by management of the Company, who takes full responsibility for its contents. This document shall
not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in any jurisdiction.
DISCLAIMER

3. •Breeding of various cannabis seeds
• Cannabis/ hops/ hemp cultivation
• Genome sequencing laboratory
• Ready to flip market (teens)
• R&D and formulations
• Import/ Export
AREV BRANDS INTERNATIONAL
British Columbia
• BC Bud Depot Seeds
Ireland
•Flowers
• Finished Products
• White labels
• Ingredients
Germany
Quebec
• cGMP production facility for finished products
• Juice, Freeze Dry, Soft gels, Capsules and Oil Extractions
• Processing of ingredients for the Canadian and International markets

4. STRATEGY – BUSINESS MODEL
AREV Cannabis Integrator
GENETICS/ BREEDING
R&D/ TRAINING
(BC Bud Depot)
OFF TAKE
AGREEMENTS
WITH LPs
EXTRACTION
FINISHED PRODUCTS
AREV BRANDS
WHITE LABELS
DISTRIBUTION
SALES
CULTIVATION LICENSES (Cordova Bay and Sorrento properties)

5. A FULLY INTEGRATED CANNABIS COMPANY
The BC Bud Depot (BCBD) acquisition allows a complete control of genetics and strategically
positioned AREV to partner with selected LPs to grow specific strains on request, combined with AREV’s
advanced extraction systems for ingredients and consumer-ready finished product lines.
AREV features:
• One of the worlds finest lines of genetics and breeding capacities and a comprehensive seed bank
with many international award winning strains
• 10 years of pre paid advertising with the most desirable ad positioning in HIGH TIMES Magazine and
a database of 60,000 patients distribution in Canada and the US
• Exclusive Canadian distribution rights to BARE Topical, an Award Winning line of topical
THC/CBD based products
• Line of THC/CBD products that target the top five specific medicinal applications
• Full line of CBD Sport Nutrition Supplements
• Over 28 acres of land in a strategic location in BC - Cannabis Act Cultivation Applicant
• Two advanced extraction systems strategically positioned in British Columbia and Quebec
for the production of CBD oil and other terpenes
• Binding LOI to acquire 100% equity stake of SEVENTAILS (Readiness for Inspection Letter Received)
AREV OVERVIEW

6. • Acquisition finalized in September 2018 to acquire the assets of B.C. Bud Depot
• Brand is recognized throughout the United States, Europe and Canada as a top marijuana seed bank
• Forty-eight (48) unique proprietary award winning strains bred by BCBD from its seed bank of hundreds of strains
• Several multiple award winners (35) at events such as the prestigious Cannabis Cup
• A premier line of genetics and breeding capacities and a comprehensive seed bank with award winning strains
• An established and recognized turn-key website platform for selling products online (60,000 registered customers)
• Award winning team of geneticists and growers to continue developing new strains and drive R&D
• Strategic partnerships with Canadian Licensed producers (LPs) to supply propriety genetics and seeds
Best for Insomnia - Night NurseBest for Anxiety - BC God Bud Best for Libido - The Purps
Best For Pain - The Black
Some of
BC Bud Depot
Exclusive Strains
EXPANDING THE BC STORY
B.C. BUD DEPOT ACQUISITION – STRATEGIC SUPPLIER TO LPs
AREV – CANNABIS INTEGRATOR

7. • AREV has bonding LOI to acquire 100% equity stake of SEVENTAILS™
• Seventails™ is located on 17 acres of ALR land ready to build in Cordova Bay, BC
• Received Security Letter Granted and Pre-License Inspection Letter from Health Canada
• Phase 1: 20,000 sq. ft. of indoor and greenhouse growing with projected yield of 2,900 kg
• Phase 2: 200,000 sq. ft. of indoor and greenhouse growing with projected yield of 25,900 kg
• Extraction capacity of 2,000 kg oil per year
LOI WITH LATE STAGE APPLICANT
SEVENTAILS™ WILL FOCUS ON HIGH-MARGIN, ORGANIC DRIED FLOWERS

8. STRATEGIC LOCATION FOR ORGANIC GROWING
28 ACRES IN SORRENTO, BC - MORTGAGE FREE
License application from the Seventails™ agreement
Construction of a genome sequencing laboratory, R&D and extraction activities
Breeding and cultivation of organic cannabis, hops and other medicinal plants
for extraction of key ingredients for use in proprietary formulations
Preparation for 60,000 sq. ft. greenhouses for seed breeding, nursery and micro cultivation

9. •AREV owns two extraction systems, ready to expand
product portfolio and product innovations
• One Supercritical CO2 and Ethanol extraction on same
platform (65 liters combined capacity) and one 20 liters
ethanol system
• ASME certification on pressure vessels (certified 2500 psi)
• Emphasis on high value raw material such as cannabis,
hemp, hops, coconut (MCTs), spices & fragrances and other
medicinal plants
• Designed and made in North America
EXTRACTION TECHNOLOGY

10. • COCO-MULSION is an innovative line of emulsified 100%
Coconut derived MCT oil (medium chain triglycerides)
and Whey Protein combined with specific nutrients for a
convenient, delicious and nutritious all-in-one-solution
• All products properly registered with Health Canada for
safety and efficacy
• Retail presence in Canada
NATURAL HEALTH PRODUCTS
COCO-MULSION – FIRST EVER EMULSIFIED COCONUT OIL WITH WHEY PROTEIN
Helps support brain functions, such as
memory, mental speed, and focus
Helps increase physical performance during
exercise and support fat metabolism
Promotes relaxation. Helps improve sleep
quality and recovery from physical activity

11. CANNABIS/ CBD PRODUCTS
BARE TOPICALS – THE MIGHTY POWER OF PLANTS TO HELP AND TO HEAL
• Line of Award Winning Cannabis Infused Topical Products aim to provides safe alternatives to achieving significant
pain relief and treatment of skin conditions
• Deeply researched formulations to bring highly effective blends of plants dominated by cannabis
• Over the counter products with Hemp Oil will be available late 2018 for traditional retail channels
BARE BERY – THE MOST DELICIOUS CANNABIS INFUSED DRINKS
• Made with Organic Apple Cider and selected BCBD strains
• All natural, No Preservative, No Sugar added

12. CANNA-MULSION delivery
system for accurate dosing of
CBD and/or THC using our
Branded product Identification
GOOD TIMES
EASY STREET
WEEKEND WARRIOR
FREQUENT FUN
WILD RIDE
CANNA-MULSION SPORT NUTRITION
Line of CBD Sport Nutrition Supplements
for the recreational market in Canada
CANNABIS and CBD PRODUCTS

13. • According to the Anxiety Disorders Association of Canada “One in four Canadians will have at least one anxiety disorder in their lifetime”
• In Canada, 58% of employees said chronic stress negatively affected their productivity while nearly half considered leaving their jobs. *2015 Mornea Shepell survey.
• In the United States alone, more than 40,000,000 people suffer from any Anxiety Disorder * National Institute of Mental Health
• Hundreds of millions of people worldwide are affected by neurological disorders* World Health Organization
•More than 30% of the population suffers from insomnia. Between 40% - 60% of people over the age of 60 Suffer from Insomnia *National Sleep Foundation
• A recent market research report indicates that more than 1.5 billion people worldwide suffer from chronic pain (100 million Americans) * Institute of Medicine of The National Academies
• “Dramatic spike in people suffering from chronic anxiety. The numbers are staggering – 41% of Canadians are at high risk for mental-health issues
• 36% felt so stressed it affected their daily lives.” *Globe & Mail – Oct 5, 2017
It is important to AREV to breed these strains to ensure consistency and the highest quality in their product lines
AREV has exclusive Sativa and Indica strains and finished products for the following medicinal symptoms:
ANXIETY • PAIN • CENTRAL NERVOUS SYSTEM • INSOMNIA • LIBIDO
MEDICINAL OILS and EDIBLES

14. • The Canadian medicinal cannabis market is estimated at nearly $800M in 2017, reaching $2.0B by 2020 (35% CAGR)
• Better perceptions from physicians toward cannabis is leading to higher registered patients and prescription rates
• New markets will open for the development of innovative products with specific medicinal applications (oil extracts,
capsules, soft gels, sprays, drops, powders, edibles)
• New distribution channels such as pharmacies, dispensaries, government stores and online will make medicinal cannabis
more accessible to patients
MEDICINAL MARKET
RECREATIONAL MARKET
• Following legalization on October 2018, the recreational market is expected to add another $2.0B by 2020
• Legalization is expected to generate high growth in the industry with demand exceeding supply. That will create an
unparalleled window of opportunity to capture the upcoming market growth
• AREV will develop brand awareness by leveraging its database of 50,000 BCBD customers and tactful advertising
in High Times Magazine
• A recent report by the Hemp Business Journal predicts that $450 million of the expected $2.0B of CBD sales by 2020
will be coming from hemp-based sources
Source: GMP Securities; PMG Research; Cormark Securities; Mackie Research
THE MARKET OPPORTUNITY

15. NILS REHMANN Ph.D
CHIEF SCIENCE OFFICER
DIRECTOR
STEPHANE MAHER
B. Comm.
CEO, DIRECTOR
SCOTT MCDERMID
DIRECTOR
Mr. Withrow is a successful natural products and
technology entrepreneur with over 25 years in public
markets. His international trade and regulatory
experience has been essential to the companies he has
structured
Mr. Trinh holds both CPA and CA designations from the
Chartered Professional Accountants of Alberta and the
Alberta Institute of Chartered Accountants. He sat on the
board of directors of the Canada China Business Council’s
Beijing Chapter and Eldorado Gold (Beijing) Management
Company Ltd. from 2013-2016
Dr. Rehmann received his PhD in pharmacology and
toxicology from the University College Dublin, Ireland, and
a Chemical Engineering degree from the University of
Applied Sciences Fresenius, Germany. His academic work
focused on extraction and purification of natural products.
Dr. Rehmann consults for Health Canada and other
government bodies.
Mr. Guy Dancosse has extensive experience in
arbitration, negotiation and mediation, nationally and
internationally, in many areas of business and the
public sector. He has undergone post-graduate
training in mediation and arbitration, successfully
completed the Director’s Education Program and is a
member of the Board of Directors and Chair of the
Human Resources Committee at the Royal Canadian
Mint.
Mr. McDermid is the proprietor of Rocky Mountain
Investments, a real-estate investment company.
Scott’s experience in land development and real
estate management extends over 20 years.
MANAGEMENT and BOARD OF DIRECTORS
Mr. Davis is a partner of Cross Davis & Company LLP Chartered
Professional Accountants. His experience includes CFO positions
of several companies listed on the CSE and the TSX Venture
Exchange. His past experience consists of senior management
positions with Appleby, Davidson & Company LLP Chartered
Professional Accountants and with Pacific Opportunity Capital Ltd.
SCOTT DAVIS, CFO
CPA, CGA
Officer
NILS REHMANN, Ph.D
Chief Science Officer,
Director
GUY DANCOSSE
Icd.D, CIRC
Director
SCOTT McDERMID
Director
STEPHANE MAHER
B.A, CEO
Director
MIKE WITHROW
Chairman
Director
Mr. Maher has 15 years of Sales and Marketing
experience and success in the Natural Products and
Food Industry. He holds a B.A. in Communications
and Law Certificate from Laval University.

16. ADVISORY BOARD
Jean Marlowe Ngo, M.Sc. is well-versed in the different areas of the pharmaceutical industry and has a strong background in Pharmacy, Drug Development and
Biobusiness. Key areas include pharmaceutical research, i.e., the use of Schisandra chinensis fruit extract called Biphenyl Dimethyl Dicarboxylate (BDD) as hepatoprotectant
and antioxidant for liver pathologies and as intravenous macronutrient preparation in surgery; international regulatory guidelines, i.e., ICH E2D, EMEA GVP, ISO 13485,
medical device classification; intellectual property, i.e., patent search and analysis, patent examination; and marketing, i.e., CME operation, medical and scientific content
for marketing materials. Research papers include “Cancer vaccine: the current therapeutic potential,” “Choice of disease endpoints in drug studies,” “Applications of
Acapulco extract,” among others. Current endeavors include understanding the mechanism of action of Cannabindiol on different receptor groups and possible applications
in neurology and cancer.
Dr. Adrian P. Wade Ph.D., C.Chem., MRSC, MCIC, MCSC - Dr. Wade is an analytical chemist and computer scientist who is currently the Chief Science Officer of
Alternative Extracts Inc. He has published over 50 scientific papers, including work in automated chemical analysis, flow injection analysis, automated extraction methods
and chromatography. He is Co-owner and Manager of Ursa Technologies Ltd. (founded 1994), which provides chemistry consulting services and undertakes research and
development in process analytical chemistry and methods development. He taught analytical chemistry at University of British Columbia (1987-94) and was a Visiting
Research Associate at Michigan State University (1985-87). He obtained his Ph.D. from University of Wales in 1985, and his B.Sc. from University of Southampton in 1981.
He serves as a Director and Officer for Alternative Extracts Inc. where he is responsible for science and methods development. Since 2005 he has served as a Director of
Goknet Mining Company Ltd., where he provides scientific and technical expertise relating to their projects in Ghana. He recently joined the Board of UC Resources Ltd as
an independent Director. He is a resident of British Columbia.
Dr. Christina Juneau is the Scientific Director at TransBIOTech and she holds a B.Sc in Biochemistry and a Ph.D. in Food Science, both from Université Laval. Dr
Juneau has more than 25 years of experience in the pharmaceutical and biotechnology industry, more specifically in the conception and development of therapeutic
products, in the manufacturing processes, in the regulatory aspects related to oral and topical drugs and natural health products development, as well as in the intellectual
properties and market introduction aspects of various compounds. She has an extensive experience in the design and management of applied R&D projects and she is the
co-author on more than 20 patents and peer reviewed scientific articles.
Dr. Shabtai Bittman - Dr. Bittman is a principal research scientist with Agriculture and Agri-Food Canada in Agassiz, BC, and previously in SK and NS, specializing in
crop production. He studied and taught Plant Ecology at McGill University and Crop Physiology (water stress) at the University of Saskatchewan. His research has been
focused on minimizing environmental impacts of food production with advanced cropping and nutrient management practices. Recent efforts include the reduction of
emissions of nitrogenous gases and particulates to the atmosphere and the improvement of water quality through strategic manure use. Dr. Bittman developed the
Canadian Agri-Environmental Health Indicator for Atmospheric Ammonia and co-chairs the UNECE Expert Panel on Mitigating Agricultural Nitrogen. He has won national
and international awards for his research accomplishments. He founded and operates the website farmwest.com.

17. FULLY DILUTED SHARE STRUCTURE – PRO FORMAT
Existing Common Shares 34,184,209
Stock Options 200,000
Warrants 8,458,600
Fully Diluted 42,842,809
* More than 85% pro forma shares closely held by company insiders
A unique opportunity to
acquire an early stage
toe-hold investment in a
closely held company.
CAPITAL STRUCTURE

18. Comparables By
Market Cap Market Cap*
Share
Price Genetics Breeding
Cultivation
License
Extraction
License
Sales
License
Dealers
License
Foreign
Partners
AREV 22 M $0.50** Y Y
YES
Through
Agreement Soon Soon Soon Y
AURORA CANNABIS INC 4.89 B $8.71 Limited N Y Y Y N Y
APHRIA INC 2.55 B $12.16 Limited N Y N Y N Y
EMERALD HEALTH THERAPEUTIC 595 M $4.40 Limited N Y N Y Y N
HARVEST ONE 117 M $0.76 Limited Limited Limited N N N Limited
MEDRELEAF CORP 2.68 B $26.50 Limited Y Y N N N Y
MARICAN GROUP 228 M $1.71 Y Rare Dank Y N N N Y
MYM NUTRACEUTICALS 154 M $1.401 N N N N N N Y
ORGANIGRAM 684 M $5.49 Limited N Y N N Y N
THC Biomed Intl Ltd $132 M $1.12 Limited N Y N Y N N
HYDROPOTHECARY CORP 937 M $4.92 Limited N Y N Y N N
CANOPY 7.95 B $39.62 Y Y Y Y Y N Y
WEED MD $220.85 M $5.44 Limited N Y N Y N N
*Data from June 6, 2018
** Pro-forma using a example of $0.50 per share for the purpose of this comparison
Competitive Comparables

19. AREV is traded on the Canadian Securities
Exchange under the symbol AREV
Canadian Headquarters:
Corporate telephone:
Corporate contacts:
Stock Exchange:
Corporate Web Site:
AREV Nutrition Sciences Inc.
Unit 2 – 9049 Shaughnessy Street
Vancouver, British Columbia
Canada, V6P 6R9
AREV Office: (778) 379-8551
Stephane Maher (604) 868-5013
Mike Withrow: (778) 896-6536
Stephane Maher, CEO
Mike Withrow, Chairman
www.arevnutrition.com
T
H
A
N
K
Y
O
U
COMPANY CONTACTS